Effectiveness of granulocyte colony-stimulating factor for patients with acute-on-chronic liver failure: a meta-analysis.

IF 1.5 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Annals of Saudi Medicine Pub Date : 2021-11-01 Epub Date: 2021-12-02 DOI:10.5144/0256-4947.2021.383

Wei Huang, Yuanji Ma, Lingyao Du, Shuang Kang, Chang-Hai Liu, Lang Bai, Xuezhong Lei, Hong Tang

{"title":"Effectiveness of granulocyte colony-stimulating factor for patients with acute-on-chronic liver failure: a meta-analysis.","authors":"Wei Huang, Yuanji Ma, Lingyao Du, Shuang Kang, Chang-Hai Liu, Lang Bai, Xuezhong Lei, Hong Tang","doi":"10.5144/0256-4947.2021.383","DOIUrl":null,"url":null,"abstract":"Background: The safety and efficacy of granulocyte colony-stimulating factor (G-CSF) for the treatment of acute-on-chronic liver failure (ACLF) remain uncertain. Therefore, we conducted a meta-analysis to draw a firmer conclusion.Methods: We searched the Cochrane library, PubMed, Embase, and China Biology Medicine disc to identify relevant RCTs performed before January 2020. Risk ratios (RRs) and their 95% confidence intervals (95% CIs) were calculated using a random effects model.Main outcome measures: RRs (95% CI) for 1-, 2-, and 3-month survival rates.Sample size: Six RCTs, including three open-label studies.Results: The six studies included 246 subjects (121 in a G-CSF group and 125 in a control group). G-CSF administration significantly improved the 1-, 2-, and 3-month survival rates in patients with ACLF. The pooled RRs (95% CI, P) were 0.43 (0.27-0.69, P=.0004), 0.44 (0.32-0.62, P<.00001), and 0.39 (0.22-0.68, P=.0009), respectively.Conclusion: G-CSF may be beneficial and effective in the treatment of ACLF, but further studies are needed to verify this conclusion.Limitations: The sample size was small, and studies were restricted to countries in Asia.Prospero registration number: CRD42021225681 CONFLICT OF INTEREST: None.","PeriodicalId":8016,"journal":{"name":"Annals of Saudi Medicine","volume":"41 6","pages":"383-391"},"PeriodicalIF":1.5000,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9b/d5/0256-4947.2021.383.PMC8650600.pdf","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Saudi Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5144/0256-4947.2021.383","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/12/2 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 6

Abstract

Background: The safety and efficacy of granulocyte colony-stimulating factor (G-CSF) for the treatment of acute-on-chronic liver failure (ACLF) remain uncertain. Therefore, we conducted a meta-analysis to draw a firmer conclusion.

Methods: We searched the Cochrane library, PubMed, Embase, and China Biology Medicine disc to identify relevant RCTs performed before January 2020. Risk ratios (RRs) and their 95% confidence intervals (95% CIs) were calculated using a random effects model.

Main outcome measures: RRs (95% CI) for 1-, 2-, and 3-month survival rates.

Sample size: Six RCTs, including three open-label studies.

Results: The six studies included 246 subjects (121 in a G-CSF group and 125 in a control group). G-CSF administration significantly improved the 1-, 2-, and 3-month survival rates in patients with ACLF. The pooled RRs (95% CI, P) were 0.43 (0.27-0.69, P=.0004), 0.44 (0.32-0.62, P<.00001), and 0.39 (0.22-0.68, P=.0009), respectively.

Conclusion: G-CSF may be beneficial and effective in the treatment of ACLF, but further studies are needed to verify this conclusion.

Limitations: The sample size was small, and studies were restricted to countries in Asia.

Prospero registration number: CRD42021225681 CONFLICT OF INTEREST: None.

Abstract Image

查看原文本刊更多论文

粒细胞集落刺激因子对急性-慢性肝衰竭患者的疗效:一项荟萃分析。

背景:粒细胞集落刺激因子(G-CSF)治疗急性慢性肝衰竭(ACLF)的安全性和有效性尚不确定。因此，我们进行了荟萃分析以得出更确切的结论。方法:我们检索了Cochrane图书馆、PubMed、Embase和中国生物医学光盘，以确定2020年1月之前进行的相关rct。采用随机效应模型计算风险比(rr)及其95%置信区间(95% ci)。主要结局指标:1个月、2个月和3个月生存率的rr (95% CI)。样本量:6项随机对照试验，包括3项开放标签研究。结果:6项研究共纳入246例受试者(G-CSF组121例，对照组125例)。G-CSF给药可显著提高ACLF患者的1、2、3个月生存率。合并RRs (95% CI, P)分别为0.43 (0.27-0.69,P= 0.0004)和0.44 (0.32-0.62,PP= 0.0009)。结论:G-CSF治疗ACLF可能有益有效，有待进一步研究证实。局限性:样本量小，研究仅限于亚洲国家。普洛斯彼罗注册号:CRD42021225681利益冲突:无

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Saudi Medicine 医学-医学：内科

CiteScore

2.80

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： The Annals of Saudi Medicine (ASM) is published bimonthly by King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. We publish scientific reports of clinical interest in English. All submissions are subject to peer review by the editorial board and by reviewers in appropriate specialties. The journal will consider for publication manuscripts from any part of the world, but particularly reports that would be of interest to readers in the Middle East or other parts of Asia and Africa. Please go to the Author Resource Center for additional information.